Novel antibiotic against Mycobacterium tuberculosis (Mtb), potently killing replicating, virulent Mtb H37Rv in a clavulanate-dependent manner

Novel potent MCT1 inhibitor, exhibiting good single agent anticancer efficacy properties

Highly potent activator of Nrf2; Potent phase 2 cytoprotective pathway inducer and liver carcinogenesis blocker

Novel TBK1/IKKε inhibitor

Novel anti-angiogenesis and vascular disrupting agent, exhibiting moderate inhibitory cell proliferation activity

Novel anti-angiogenesis and vascular disrupting agent, exhibiting moderate inhibitory cell proliferation activity

Novel agonist for nicotinic acetylcholine receptors (nAChRs), modestly selectively targeting α6β2 subtype

Novel potent and selective ligand of Brd2(2)

Aquaporin 1 (AQP1) channel blocker

Potent CB1 receptor inverse agonist

Novel orally bioavailableγ-secretase modulator, reducing Aβ42 levels

Potent formyl peptide receptor 2 (FPR2) agonist

Potent and selective antagonist of adenosine A2A receptors

Non-competitive modulator of the proteasome inducing apoptosis a panel of myeloma and leukemia cell lines

Novel TRPM8 channel blocker

Potent TRPM8 antagonist, exhibiting antiallodynic properties in pain models

Antimalarial; Novel inhibitor of HepG2

Novel Inhibitor of the malaria parasite protein kinase CLK3, inhibiting the development of liver-stage parasites, killing asexual blood-stage parasites at the trophozoite and schizont stages of the erythrocytic cycle, blocking the development of sexual ga

Highly potent NR2B-selective NMDA receptor antagonist

Nonpeptide partial agonist of oxytocin (OT) and vasopressin V2 receptors

Potent and selective polo-like kinase 2 (PLK2) inhibitor

Novel potent and selective CHK1 kinase inhibitor